Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARIMA: Secukinumab CV Risk Markers in Psoriasis
NCT02559622Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in chronic plaque psoriasis, sponsored by Novartis. Started Apr 2014; status: completed.
02
Drugs
secukinumab
03
Conditions
chronic plaque psoriasis
Beyond the preview
Go deeper on NCT02559622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559622.